Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Americans For Medical Advancement and treatments meant for humans. As a result, drug development should be quicker and more affordable. AFMA also wants to see medical research funding directed to more relevant areas of research that are often forgotten and not used. Some examples of scientific fields that AFMA believes are not applied enough when researching and creating drugs include complexity science, developmental biology, evolutionary biology, genetics and personalized medicine. Additional goals that the organization has are to have the requirements for animal testing reevaluated through the U.S. Food and Drug Administration and United States Environmental Protection Agency. AFMA also wants influential institutions such